According to the results from a recent large study, Eli Lilly's diabetes drug Jardiance -- co-marketed with Boehringer Ingelheim -- is the first blood-sugar lowering drug ever to reduce the risk of heart attacks, strokes, and cardiovascular deaths.
Lilly and Boehringer said the favorable results for Jardiance were seen in a 7,000-patient study of patients with type 2 diabetes considered at high risk of heart attacks and stroke.
Competing diabetes drugs, such as Merck’s Januvia and AstraZeneca’s Onglyza, have thus far failed to replicate these results. Januvia and Onglyza are a class of drugs called DPP-4s, while Jardiance is an SGLT-2 inhibitor.
Some analysts believe this study to be a potentially paradigm shifting trial that will result in Jardiance becoming the oral drug of choice after metformin.
Read the Forbes article